Your browser is not supported for the Live Clock Timer, please visit the Support Center for support.

Glenmark launches fixed doze combination for adult with type 2 diabetes

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

 

  • Glenmark is the first company in the world to launch Remogliflozin (100 mg) + Vildagliptin (50 mg) Fixed Dose Combination (FDC)
  • The FDC will be marketed under two brand names Remo V and Remozen V
  • Remogliflozin is an innovative, patent-protected sodium glucose co-transporter-2 (SGLT2) inhibitor indicated for the treatment of Type 2 diabetes in adults
  • With this launch, the company aims to increase patient access to SGLT2 inhibitors & DPP4 inhibitors which have proven benefits in the effective management of diabetes
  • Glenmark’s Remo V and Remozen V are priced at Rs. 14 per tab, Rs. 28 per day cost of therapy which is 65% lower than the other available SGLT2 & DPP4 combination brands in India

 

 Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination (FDC) of its novel, patent protected and globally researched Sodium Glucose Co-Transporter Inhibitor (SGLT2i) – Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, in India. The fixed drug combination is indicated for the management of Type 2 diabetes. The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo V and Remozen V.

Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin fixed dose combination and India is the first country to get access to this FDC drug. Glenmark received approval from the DCGI (the drug approval authority in India) for manufacturing and marketing Remogliflozin + Vildagliptin combination in late November 2020.

Globally, SGLT2 inhibitors & DPP4 inhibitors are emerging as the preferred treatment option for the management of Type 2 diabetes. Glenmark has been at the forefront in providing access to the latest treatments at a low cost for patients with diabetes in India.

In chronic diseases like Type 2 diabetes, patients are required to consume multiple anti-diabetic drugs for prolonged periods of time. Moreover, in India, patients have to bear the drug cost on their own and so the price of the drug becomes a major factor that impacts treatment adherence. While the average daily cost of therapy of existing brands in the same drug category is Rs. 78,  Glenmark’s Remogliflozin-Vildagiptin combination has been launched at a breakthrough price of Rs. 14 per tablet, to be taken twice daily; which amounts to Rs. 28 as the per day cost of therapy. This cost is 65% lower than the other available SGLT2 & DPP4 combination drugs in the market.

Glenmark’s Remogliflozin + Vildagliptin combination will significantly improve access and bring a world class and well researched combination product at an affordable price to patients in India. This combination has been approved by the DCGI, the drug regulator in India for adults aged 18 years and older with Type 2 diabetes to improve glycemic control when metformin and one of the mono-components of fixed dose combination do not provide adequate glycemic control, or when already being treated with separate doses of Remogliflozin & Vildagliptin.

“Glenmark has been a pioneer in providing access to the latest treatment options to diabetes patients in India. We are glad to introduce this innovative fixed dose combination, which is cutting-edge, extensively researched and at an affordable cost for patients in the country. Diabetes is a key area of focus for Glenmark and the launch of this product will enable us to improve access to diabetes treatment by providing an effective, high quality, world-class and affordable treatment option to patients in India,” said Mr. Alok Malik, Group Vice President & Business Head, India Formulations.

In 2015, Glenmark revolutionized the diabetes market by launching its DPP4 inhibitor – Teneligliptin at a price that was approximately 55% lower than the other DPP4 inhibitors available in India at that time. Continuing the legacy, Glenmark launched its globally researched, innovator molecule Remogliflozin in 2019, at a price around 55% lesser than other SGLT2 inhibitors available in the Indian market at that time.  According to the International Diabetes Federation (IDF), the prevalence of diabetes in India is 8.9% with around 77 million adults living with diabetes as of 2019.

More News from business, Health

Hemalini shares a memoir

  CNM Movie Reporter Bollywood dream girl Hema Malini is all set to make a comeback with Shimla Mirchi. Meanwhile, the actor shared an early picture of her film. The picture is very specific. This photo taken by Hemalini in the guise of Goddess is now the talk of the fans. The actor says that she […]

Renji Panicker to release first look teaser of ‘Oru Canadian Diary’

CNM Movie Reporter Debut director Seema Sreekumar who is the granddaughter of poet Kunhiraman Nair,directs the movie Actor-director Renji Panicker will release the first look teaser of ‘Oru Canadian Diary’, directed by debut director Seema Sreekumar under the banner of Sreem Productions, on his official Facebook page at 6 pm on October 14. The movie’s […]

Bollywood actor Saif Ali Khan as Ravana in Prabhas movie Adipurush

Bollywood actor Saif Ali Khan will play the role of Ravana in Prabhas’ movie Adipurush, which is being prepared by Om Rout based on the Ramayana story. This is the first time Prabhas and Saif Ali Khan have teamed up. Prabhas made the announcement on his social media account. Prabhas shared the poster saying that […]

Recent News

Education

Job openings at IIM-Kozhikode&Kochi campuses

January 25, 2021

CNM Career Reporter Recruitment of Support Engineer (IT) on contract Notification No. C-01/2021-IIMK.HR dated 18/01/2021. Indian Institute of Management, Kozhikode invites online applications from eligible candidates for one position of Support Engineer (IT) on contract at IIMK-Kochi Campus Office, Athulya Building, Infopark, Kakkanad, Ernakulam. Job Specification- Educational Qualification M.Tech (Computer Engineering & Network Technology/Computer Science and Engineering / Computer Network Engineering/equivalent)/M.Sc (Computer […]

Vedic IAS Academy launches scholarship program

CNM Reporter Vedic IAS Academy has launched its Vedic Erudite Scholarship Program  in Malabar with the aim of supporting IAS aspirants in the region. Transport Minister AK Sasindran inaugurated the program at a function held at Parambil Bazaar Alba Auditorium in Kozhikode. “ Civil Service is not an impossible task as many think. We need to mold socially responsible and efficient people in […]

December 27, 2020

Faculty deans appointed at Malayalam University

CNM Reporter Thunchath Ezhuthachan Malayalam University has appointed new faculty deans. Dr. TB Dr. Venugopal Panicker (Faculty of Malayalam Studies); C.P. Dr. Achuthanunni (Faculty of Literature), Kalamandalam Haimavathi (Faculty of Arts); Dr. MR Raghav Warrier (Heritage Faculty); KG Paul (Faculty of Traditional Knowledge Systems), prof. K. Karna Maharajan (Faculty of Media), Dr. P.K. . Poker […]

December 18, 2020

More News